Arax Advisory Partners’s MaxCyte MXCT Stock Holding History

Arax Advisory Partners’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.6K	Buy	31,378 +31,151	+13,723%	+$31K	﹤0.01%	3478
2026 Q1	$308	Buy	+227	New	+$212	﹤0.01%	3486
2025 Q4	–	Sell	-2,121	Closed	-$3.35K	–	4375
2025 Q3	$3.35K	Buy	+2,121	New	+$3.69K	﹤0.01%	2980

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Arax Advisory Partners's MXCT Position: Q2 2026 in Review

Arax Advisory Partners increased its MaxCyte (MXCT) stake by 13,723% in Q2 2026, buying an estimated $31K and bringing the position to 31,378 shares worth $38.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3478.

Arax Advisory Partners first reported a position in MXCT in Q3 2025 and has held it in 3 quarters since. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Arax Advisory Partners held 31,378 shares of MaxCyte worth $38.6K as of Q2 2026.
Arax Advisory Partners bought 31,151 MaxCyte shares in Q2 2026, an estimated $31K.
MaxCyte made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3478 holding.
Arax Advisory Partners first reported a position in MaxCyte in Q3 2025 and has held it in 3 quarters since.
122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.